Co-Deletion of A238L and EP402R Genes from a Genotype IX African Swine Fever Virus Results in Partial Attenuation and Protection in Swine

Figures

• 

  Figure 1. Body temperature and clinical scores: Rectal temperatures in individual pigs inoculated with 102 HAD50 of ASFV-Ke (A) or 102 TCID50 ASFV-Ke-∆A238L (B). Mean +/− SEM of rectal temperatures in ASFV-Ke (black) and ASFV-Ke-∆A238L (maroon) groups (C). Cumulative clinical scores in pigs inoculated with ASFV-Ke (D) or ASFV-Ke-∆A238L (E). Mean +/− SEM of cumulative clinical scores in ASFV-Ke (black) and ASFV-Ke-∆A238L (maroon) groups (F).

• 

  Figure 2. Virus replication in the blood (viral genome copies) after inoculation with 102 TCID50 of ASFV-Ke (black) or ASFV-Ke-∆A238L (maroon).

• 

  Figure 3. ASFV-specific antibody response after inoculation with ASFV-Ke-∆A238L. The percentage of blocking by p72-specific serum antibodies at indicated times was tested using a commercial competitive ELISA. The threshold range is indicated by a grey bar.

• 

  Figure 4. Body temperatures and clinical scores: Rectal temperatures in individual pigs mock-immunised with PBS (A) or immunised with 102 TCID50 of ASFV-Ke-∆EP402R∆A238L (B) before and after challenge with ASFV-Ke. Mean +/− SEM of rectal temperatures in PBS (blue) and ASFV-Ke-∆EP402R∆A238L (red) (C) and ASFV-Ke challenged groups. Cumulative clinical scores in pigs mock-immunised with PBS (D) or ASFV-Ke-∆EP402R∆A238L-immunised (E) and ASFV-Ke challenged groups. Mean +/− SEM of cumulative clinical scores in mock-immunised (blue) and ASFV-Ke-∆EP402R∆A238L-immunised (red) (F) and ASFV-Ke challenged groups.

• 

  Figure 5. Virus replication in the blood (viral genome copies) after immunisation with PBS (blue) or ASFV-Ke-∆EP402R∆A238L (red) and subsequent challenge with ASFV-Ke (A). Detection of virus DNA in tissues prepared post-mortem from animals immunised with PBS (blue) or ASFV-Ke-∆EP402R∆A238L (red) after challenge with ASFV-Ke (B).

• 

  Figure 6. ASFV-specific antibody and cellular immune responses: percentage of blocking by p72-specific serum antibodies after mock-immunisation with PBS (A) or immunisation with ASFV-Ke-∆EP402R∆A238L (B) determined using a commercial blocking ELISA. Mean+/−SEM of percentage blocking in PBS- or ASFV-Ke-∆EP402R∆A238L-immunised groups (C). IFNγ ELISPOT using PBMC isolated from animals at day 28 after immunisation with PBS (blue) or ASFV-Ke-∆EP402R∆A238L (red) and stimulation with either medium or ASFV-Ke wild type (wt) infection at an MOI of 0.1 (D).